Published:
CEL-SCI CORPORATION Releases Letter to Shareholders
VIENNA, Va., Aug. 20 /PRNewswire-FirstCall/ -- The following letter is
being released by CEL-SCI CORPORATION (Amex: CVM) to its shareholders:
Dear Fellow Shareholders,
I am writing to you in response to the many phone calls and e-mails that
we received within the last 24 hours. You were universally enthused by the
licensing deal for our Phase III cancer drug Multikine with one of the most
successful and respected pharmaceutical companies in the world. You were
excited that they are putting their reputation on the line by actually running
and funding the costs of a part of our Phase III clinical trial. You were
enthused with the initial increase in the share price, yet no one could
understand why our shares, after trading 30 times the normal volume, took such
a steep fall in the afternoon. You asked, "How is it possible that the stock
can be down after such a good announcement?" As the Company's largest
shareholder, and somebody who has purchased shares in the open market
regularly, I am as puzzled and disappointed as you.
While we may never know what happened, I have been told by many that the
stock traded as if it could have been under an attack from short sellers.
Short sellers play a role in the stock market, correcting imbalances in supply
and demand that occur periodically. However, it appears that trading in our
shares may have involved more than opportunistic short sellers, but may
actually have involved manipulation, which is illegal.
Short sellers make money by betting that a stock will decline in price.
They sell shares they do not own (yes that is legal as long as you follow
certain rules which we think were not followed in this case) and hope to
repurchase them at a lower price. Short sellers may look for companies that
have been doing better than the averages and/or their peers on the theory that
everyone should be knocked down equally. Our share price has been doing much
better than the averages and/or our peers in what has been a very challenging
market for micro-cap stocks.
We believe that in all likelihood the short seller has been shorting
CEL-SCI stock for a while. The selling of our stock increased in the last
month, but more importantly, the seller was not acting like a shareholder, but
like someone who trades deceptively to create the impression of a decreasing
share price. Remember, the short seller makes money from a declining share
price. For example, one day we traded about 85,000 shares throughout the day
and in the last minute another 80,000 shares were sold. That may have been
done to drive the share price down and is euphemistically known as "painting
the tape," an illegal activity which makes the stock look weak and
unattractive.
Yesterday's announcement of the licensing deal brought in a large amount
of buying to our stock and initially increased the share price substantially
on huge volume. Having been taken by surprise by this great news, the short
seller may have been faced with taking a large loss (having to buy back at
higher prices the shares that he sold earlier) or selling again a very large
number of shares in order to drive down the share price and stop the share's
upward momentum. It appears that he may have opted for shorting many more
shares. And again, in the last few minutes of the day's trading, large amounts
of stock were sold depressing our share price.
The goal of the short seller may have been to scare investors out of their
stock at lower prices so that the short seller can cover (buy the shares back)
at a profit (a lower price). So what can you do about this? Short sellers can
benefit from creating panic among the shareholders and getting them to sell
their shares cheaply. Therefore CEL-SCI shareholders should be aware of the
game that is being played with their Company's shares and not be intimidated.
We accept that short selling is a legal activity, but only when conducted
according to the rules. WE BELIEVE THAT SHORT SELLERS IN OUR CASE MAY NOT HAVE
FOLLOWED THE RULES AND THAT IS WHY WE NEED YOUR HELP. WE NEED YOU TO CONTACT
YOUR CONGRESSPERSON AND/OR SENATOR AS EXPLAINED AT THE END OF THE LETTER.
Short selling CEL-SCI stock is allowed ONLY if you can borrow an
equivalent amount of CEL-SCI stock. We have checked with brokers and it is
very difficult to borrow CEL-SCI shares. Therefore, it is highly unlikely that
the massive short sales that have hurt the CEL-SCI share price are legal short
sales which have been transacted with a corresponding number of shares
borrowed. Most likely these sales were conducted in violation of the short
sale rules. These sales were most likely conducted to keep the share price
from gaining upward momentum since an increase in the share price would hurt
the short seller. If we are correct, we are the victim of vicious and illegal
manipulation.
The only way to prove this malfeasance, or disprove it, is to get the
regulators to subpoena the trading records of the last few weeks. Only they
can find out whether short sellers may have followed the rules. That is where
you can be of great help. Twice in the last month we have contacted the SEC
and other regulatory bodies and have asked them to investigate. Now we are
asking you to contact your local Congressman and/or Senator and request their
help in getting the regulators to focus on our issue. Short sellers must abide
by the rules. CEL-SCI was created to help people. Now CEL-SCI needs your help.
In attacking CEL-SCI, they are attacking not just your money but also the
hope of cancer patients. This affects almost every family. Our Multikine is a
late stage cancer drug that appears to be non-toxic and showed significant
increases in survival in the Phase II studies. Hence, by jeopardizing the
Company, short sellers may be destroying the dreams of many people seeking a
novel and non-toxic cancer treatment. I have dedicated 20 years to the
development of this drug. We are about to enter the end stage and we are
starting to find acceptance even among the big pharmaceutical companies, and I
am not going to let these people push us around. I and the management and
scientific team at CEL-SCI remain steadfast in our commitment to bring this
promising drug to market.
Thank you for your help,
Geert Kersten
Chief Executive Officer
SOURCE CEL-SCI CORPORATION
Copyright © 2009, PRNewswire
newsblaze
Copyright © 2009, NewsBlaze,
Daily News
Tags: ,MTC,HEA,VA-CEL-SCI-Shrholders
_ _Is your favorite bookmark site missing?
Ask for it.